Research press release


Nature Medicine

Non-invasive tumor burden screening


Maximilian Diehnたちは、400人を超える患者のデータを利用して、肺がんに頻発する突然変異を網羅するシークエンシング法を開発した。この方法によって、ステージII以上のがんを持つ別の患者群由来の試料の場合は全てから、またステージIの患者由来の試料の場合はその半数から、高感度でctDNAが検出された。検出されたctDNA量は、治療過程での腫瘍量に比例し、治療後に残存腫瘍のある患者が同定でき、治療に対する反応性をX線法よりもうまく調べられた。


An ultrasensitive method for measuring circulating tumor DNA (ctDNA), a non-invasive biomarker for quantifying cancer burden in patients is reported online this week in Nature Medicine. This method is more useful than existing techniques, as it is cheaper, provides both high sensitivity and can be used one patients with various different tumor genotypes, for which recurrent mutation data is known.

Maximilian Diehn and colleagues used data from over 400 patients to develop a sequencing approach that covers recurrent gene mutations in lung cancer. With this method, they detected ctDNA with high specificity in all samples from another set of patients with stage II and advanced disease and half of the samples from stage I cancer patients. The amounts of ctDNA measured correlated with tumor volume during the course of therapy, identified patients with residual disease after treatment, and better detected response to therapy compared to radiographic methods.

As this method may also allow cancer screening and genetic identification of locally advanced and metastatic tumors without needing a biopsy, it could be used in the clinic for personalized cancer treatment.

doi: 10.1038/nm.3519


メールマガジンリストの「Nature 関連誌今週のハイライト」にチェックをいれていただきますと、毎週各ジャーナルからの最新の「注目のハイライト」をまとめて皆様にお届けいたします。